Phase III Study Validates Taphalgin‘s Efficacy for Cancer Pain Management

19.05.2022

Our commitment to pain relief has never been stronger. Today, we celebrate the successful completion of Phase III open-label comparative multicentre randomized trial of Taphalgin for cancer pain management. The results further reinforce our belief in Taphalgin's promise and potential in the pharmaceutical market.

Phase III Study Validates Taphalgin‘s Efficacy for Cancer Pain Management

About

Recent news

Taphalgin Completes Another Successful Phase III Clinical Study for Postoperative Pain

Phase III Study Validates Taphalgin‘s Efficacy for Cancer Pain Management

Сontacts

©2016-2023 PVP LABS PTE. LTD